Corcept Therapeutics Files 8-K

TL;DR

Corcept filed a routine 8-K on 12/30/24, no major news.

AI Summary

Corcept Therapeutics Inc. filed an 8-K on December 30, 2024, reporting on other events and financial statements. The filing does not contain specific financial figures or details about material events beyond its routine reporting nature.

Why It Matters

This 8-K filing from Corcept Therapeutics Inc. serves as a routine update to the SEC, indicating that the company has submitted necessary financial statements and reported on other events as of December 30, 2024.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not disclose any new material events, risks, or significant financial changes.

Key Players & Entities

• Corcept Therapeutics Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• 101 Redwood Shores Parkway, Redwood City, CA 94065 (address) — Principal Executive Offices
• December 30, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value CORT The Nasdaq Stock Mar

Filing Documents

• d834253d8k.htm (8-K) — 22KB
• d834253dex991.htm (EX-99.1) — 8KB
• g834253g1231022334258.jpg (GRAPHIC) — 5KB
• 0001193125-24-286917.txt ( ) — 156KB
• cort-20241230.xsd (EX-101.SCH) — 3KB
• cort-20241230_lab.xml (EX-101.LAB) — 17KB
• cort-20241230_pre.xml (EX-101.PRE) — 11KB
• d834253d8k_htm.xml (XML) — 3KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 30, 2024 Date of Report (date of earliest event reported) Corcept Therapeutics Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50679 77-0487658 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 101 Redwood Shores Parkway , Redwood City , CA 94065 (Address of Principal Executive Offices) (Zip Code) (650) 327-3270 Registrant's telephone number, including area code Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value CORT The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item8.01. Other Events. On December 30, 2024, Corcept Therapeutics Incorporated (the "Company") issued a press release announcing that the Company has submitted a new drug application to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing's syndrome). The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item9.01. Financial Statements and Exhibits (d) Exhibits Exhibits No. Description 99.1 Press Release of Corcept Therapeutics Incorporated, dated December 30, 2024 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORCEPT THERAPEUTICS INCORPORATED Date: December 30, 2024 By: /s/ Atabak Mokari Name: Atabak Mokari Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR